The slate and the radar

The slate we cover, and what is on the radar

Three lists. The slate: the clinical trial readouts, FDA decisions and advisory committee meetings we have committed to cover, each with its expected window and, once published, the hash of its bar. The radar: catalysts our scans have found and the slate does not cover yet, each with where its date comes from. The exclusions: what we looked at and decided against. This is not a complete calendar of the sector; it is everything we have looked at, in the open. An event joins the slate before its result exists, and one we drop stays listed as dropped.

The slate

Event	Kind	Window	Tier	Status	Bar
$ATTO — ATTO-1310 chronic pruritus and high-itch atopic dermatitis	Trial results	2026-01-01 – 2026-12-31 timing unconfirmed	contested	dropped	not published
$IMCR — KIMMTRAK (tebentafusp) Previously treated advanced melanoma	Trial results	2026-01-01 – 2026-12-31 timing unconfirmed	contested	slate	not published
$MIRM — brelovitug hepatitis D virus (HDV) infection	Trial results	2026-01-01 – 2026-12-31 timing unconfirmed	contested	slate	not published
$VSTM — VS-7375 mCRC and mPDAC	Trial results	2026-01-01 – 2026-12-31 timing unconfirmed	contested	slate	not published
$BHVN — BHV-7000 refractory focal epilepsy	Trial results	2026-07-01 – 2026-12-31 timing unconfirmed	contested	dropped	not published
$ABOS — sabirnetug (ACU193) Alzheimer's disease	Trial results	2026-09-01 – 2026-12-31 timing unconfirmed	contested	dropped	not published
$EVMN — EVO301 Moderate-to-severe atopic dermatitis	Trial results	2026-10-01 – 2026-10-01 timing unconfirmed	marquee	bar_published	`6b7f85aac708eff72be3f64923bf1e6f458ac1e57ff7d63cb925a1fd4105e866`
$IVVD — VYD2311 COVID-19 pre-exposure prophylaxis	Trial results	2026-10-01 – 2026-10-31 timing unconfirmed	marquee	bar_published	`13f46bbcf995a82f3d6eb21cc6c5c02936aa8734e66f307a9a93ac8564f10b7a`
$PCVX — VAX-31 adult pneumococcal disease	Trial results	2026-10-01 – 2026-10-31 timing unconfirmed	marquee	bar_published	`7497f8b0abfee8cac8baf9d1906706d0333c82f8ba7aca36298bc84c8ac5c0e1`
$SYRE — SPY072 Psoriatic Arthritis (PsA), Axial Spondyloarthritis (axSpA)	Trial results	2026-10-01 – 2026-12-31 timing unconfirmed	contested	slate	not published
$ZBIO — obexelimab Systemic Lupus Erythematosus (SLE)	Trial results	2026-10-01 – 2026-12-31 timing unconfirmed	marquee	slate	not published
$KOD — KSI-101 Macular edema secondary to inflammation (MESI)	Trial results	2026-12-01 – 2026-12-31 timing unconfirmed	marquee	bar_published	`11987fd3719caf576d6019b042d6758a5e06c84ad1ae7db01084c5391f36220b`
$RZLT — ersodetug Tumor hyperinsulinism (tumor HI)	Trial results	2026-12-01 – 2026-12-31 timing unconfirmed	marquee	bar_published	`8f930339f9c4670b07ab0b4fa0ebeed8275a86d0a62266e84d3af6605f7096ab`
$ALKS — ALKS 7290 Attention-deficit hyperactivity disorder (ADHD) in adults	Trial results	2027-01-01 – 2027-12-31 timing unconfirmed	contested	slate	not published
$DYN — z-basivarsen (DYNE-101) Myotonic dystrophy type 1 (DM1)	Trial results	2027-01-01 – 2027-03-31 timing unconfirmed	contested	slate	not published
$GPCR — ACCG-2671 Obesity	Trial results	2027-01-01 – 2027-06-30 timing unconfirmed	contested	slate	not published
$IKT — IKT-001 Pulmonary arterial hypertension (PAH)	Trial results	2027-01-01 – 2027-06-30 timing unconfirmed	contested	slate	not published
$LBRX — LB-102 schizophrenia	Trial results	2027-01-01 – 2027-06-30 timing unconfirmed	contested	dropped	not published
$MANE — VDPHL01 Female pattern hair loss	Trial results	2027-01-01 – 2027-06-30 timing unconfirmed	contested	slate	not published
$OCGN — OCU400 Retinitis pigmentosa	Trial results	2027-01-01 – 2027-03-31 timing unconfirmed	contested	slate	not published
$OCGN — OCU410ST Stargardt Disease	Trial results	2027-01-01 – 2027-12-31 timing unconfirmed	marquee	slate	not published
$PYXS — Micvotabart pelidotin (MICVO) Second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC)	Trial results	2027-01-01 – 2027-06-30 timing unconfirmed	contested	slate	not published
$RNAC — Descartes-08 Generalized myasthenia gravis	Trial results	2027-01-01 – 2027-12-31 timing unconfirmed	contested	slate	not published
$TRDA — ENTR-601-45 Duchenne muscular dystrophy (DMD)	Trial results	2027-01-01 – 2027-06-30 timing unconfirmed	contested	dropped	not published
$TTRX — GX-03 Moderate-to-severe atopic dermatitis	Trial results	2027-01-01 – 2027-03-31 timing unconfirmed	contested	slate	not published
$ANAB — Jemperli (dostarlimab) Untreated stage II/III dMMR/MSI-H locally advanced rectal cancer	FDA decision	2027-02-01 – 2027-02-28 timing unconfirmed	marquee	bar_published	`008a6a6f3ce55f74a14d914bee95fc5b0f3de6452187d60aee16057cf570f01b`

On the radar

Catalysts our scans have found that the slate does not cover yet, soonest first, and why not. Every date says where it comes from. Company-guided is a sentence in an SEC filing, linked. Registry estimate is the primary completion date on ClinicalTrials.gov: the day the trial’s last measurement is due, not the day results are announced. Results follow it, and the company has not said when. The scans read companies between $200 million and $10 billion in market value, so this is what they met, not every catalyst there is.

A date says when; it does not say how much rides on it. So each row also carries a count from the registry: how many Phase 2 or 3 trials the company has that have finished enrolling and not yet reported. One of one at a $300 million company is a readout the company rides on; one of six is not, and one of one at a company worth billions may not be, which is why the market value is printed beside the count. The count covers trials the company leads and is matched to it by name, so a blank means unknown, never none, and trials still enrolling are not in it.

Two more lines come from the company’s own filings, when they are there. No approved products means its latest quarterly or annual report says so in those words, and the report is linked; a company whose report does not say it is left unmarked, which is not the same as having a drug on the market. How long the cash lasts is printed only in the company’s own words, in quotation marks, when its latest report gives a year; we do not estimate it. A company whose reported operating cash flow was not negative is marked as generating cash. Rows run soonest month first; within a month, companies that say they have no approved product come first, then the fewest trials awaiting results, then the smallest company.

Catalyst	What	When, and who says so	What rides on it	Why it is not on the slate
$MLTX — MoonLake Immunotherapeutics — sonelokimab An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)	Trial results Phase 3	primary completion 2026-09-28 registry estimate NCT06768671	1 of 2 late-stage trials awaiting results $974M market value no approved products, says its 10-Q, 2026-08-10	registry date only — waiting for the company to guide one
$OCGN — Ocugen, Inc. — OCU410ST A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease	Trial results Phase 2/3	primary completion 2026-09-28 registry estimate NCT05956626	1 of 3 late-stage trials awaiting results $370M market value no approved products, says its 10-K, 2026-03-04	this drug is on the slate
$IBRX — ImmunityBio, Inc. — ALT-803 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer	Trial results Phase 1/2	primary completion 2026-09-30 registry estimate NCT02138734	1 of 3 late-stage trials awaiting results $9.4B market value	registry date only — waiting for the company to guide one
$OLMA — Olema Pharmaceuticals, Inc. — OP-1250 (Palazestrant) OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer	Trial results Phase 3	primary completion 2026-10-31 registry estimate NCT06016738	1 of 1 late-stage trial awaiting results $747M market value no approved products, says its 10-Q, 2026-08-10 “fund our current operating plan through mid-2028” · 10-Q, 2026-08-10	registry date only — waiting for the company to guide one
$ANNX — Annexon, Inc. — Vonaprument (formerly ANX007) A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)	Trial results Phase 3	primary completion 2026-10-31 registry estimate NCT06510816	1 of 1 late-stage trial awaiting results $783M market value no approved products, says its 10-Q, 2026-08-12 “fund operating expenses into 2028” · 10-Q, 2026-08-12	registry date only — waiting for the company to guide one
$SYRE — Spyre Therapeutics, Inc. — SPY072 A Study of SPY072 in Rheumatic Disease	Trial results Phase 2	primary completion 2026-10-31 registry estimate NCT07148414	1 of 1 late-stage trial awaiting results $7.5B market value no approved products, says its 10-Q, 2026-08-04	this drug is on the slate
$ABOS — Acumen Pharmaceuticals, Inc. — Sabirnetug A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)	Trial results Phase 2	primary completion 2026-10-01 registry estimate NCT06335173	— $162M market value no approved products, says its 10-Q, 2026-08-12 “fund our operations into early 2027” · 10-Q, 2026-08-12	dropped from the slate
$PHAT — Phathom Pharmaceuticals, Inc. — vonoprazan A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks	Trial results Phase 2	primary completion 2026-10-01 registry estimate NCT06851559	1 of 1 late-stage trial awaiting results $595M market value	registry date only — waiting for the company to guide one
$IMCR — Immunocore Holdings plc — IMC-F106C Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors	Trial results Phase 1/2	primary completion 2026-10-01 registry estimate NCT04262466	1 of 1 late-stage trial awaiting results $1.6B market value generating cash from operations · XBRL, to 2026-06-30	registry date only — waiting for the company to guide one
$OGN — Organon & Co. — Tapinarof Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects	Trial results Phase 3	primary completion 2026-10-01 registry estimate NCT05172726	1 of 1 late-stage trial awaiting results $3.6B market value generating cash from operations · XBRL, to 2026-06-30	registry date only — waiting for the company to guide one
$SRPT — Sarepta Therapeutics, Inc. — eteplirsen A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)	Trial results Phase 3	primary completion 2026-10-31 registry estimate NCT03992430	1 of 2 late-stage trials awaiting results $2.0B market value	registry date only — waiting for the company to guide one
$RYTM — Rhythm Pharmaceuticals, Inc. — Setmelanotide A Study of Setmelanotide in Patients With Prader-Willi Syndrome	Trial results Phase 2	primary completion 2026-10-31 registry estimate NCT06772597	1 of 2 late-stage trials awaiting results $6.6B market value	registry date only — waiting for the company to guide one
$TGTX — TG Therapeutics, Inc. — ublituximab A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)	Trial results Phase 3	primary completion 2026-10-31 registry estimate NCT07211633	1 of 2 late-stage trials awaiting results $8.6B market value generating cash from operations · XBRL, to 2026-06-30	registry date only — waiting for the company to guide one
$MIRM — Mirum Pharmaceuticals, Inc. — Maralixibat Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)	Trial results Phase 3	primary completion 2026-10-01 registry estimate NCT06553768	1 of 4 late-stage trials awaiting results $5.7B market value	registry date only — waiting for the company to guide one
$SLGL — Sol-Gel Technologies Ltd. — Patidegib Gel 2% Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome	Trial results Phase 3	primary completion 2026-10-01 registry estimate NCT06050122	— $237M market value	registry date only — waiting for the company to guide one
$BIOA — BioAge Labs, Inc. — BGE-102 A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors	Trial results Phase 2	primary completion 2026-11-30 registry estimate NCT07656727	1 of 1 late-stage trial awaiting results $328M market value no approved products, says its 10-Q, 2026-08-05 “fund our operations and capital expenses through 2029” · 10-Q, 2026-08-05	registry date only — waiting for the company to guide one
$TECX — Tectonic Therapeutic, Inc. — TX000045 A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)	Trial results Phase 2	primary completion 2026-11-24 registry estimate NCT06616974	1 of 1 late-stage trial awaiting results $456M market value no approved products, says its 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$TYRA — Tyra Biosciences, Inc. — TYRA-300 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations	Trial results Phase 1/2	primary completion 2026-11-01 registry estimate NCT05544552	1 of 1 late-stage trial awaiting results $1.5B market value no approved products, says its 10-K, 2026-03-02 “fund our operating expenses and capital expenditures into the second half of 2028” · 10-Q, 2026-08-04	registry date only — waiting for the company to guide one
$ERAS — Erasca, Inc. — ERAS-007 A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors	Trial results Phase 1/2	primary completion 2026-11-01 registry estimate NCT04866134	1 late-stage trial awaiting results at this company $5.0B market value no approved products, says its 10-Q, 2026-08-11	registry date only — waiting for the company to guide one
$ZURA — Zura Bio Ltd — Tibulizumab Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense	Trial results Phase 2	primary completion 2026-11-01 registry estimate NCT06993610	1 of 2 late-stage trials awaiting results $383M market value no approved products, says its 10-Q, 2026-08-11 “fund our operating expenses and capital requirements through at least the end of 2028” · 10-Q, 2026-08-11	registry date only — waiting for the company to guide one
$CGON — CG Oncology, Inc. — cretostimogene grenadenorepvec A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Trial results Phase 3	primary completion 2026-11-01 registry estimate NCT06111235	1 of 2 late-stage trials awaiting results $6.3B market value no approved products, says its 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$ARVN — Arvinas Inc. — ARV-806 A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation	Trial results Phase 1/2	primary completion 2026-11-30 registry estimate NCT07023731	1 of 1 late-stage trial awaiting results $490M market value “our estimates regarding expenses, future revenues, capital requirements and needs for additional financing, and statements regarding our cash, cash …” · 10-Q, 2026-08-04	registry date only — waiting for the company to guide one
$SLDB — Solid Biosciences Inc. Microdystrophin Gene Transfer Study in Adolescents and Children With DMD	Trial results Phase 1/2	primary completion 2026-11-30 registry estimate NCT03368742	1 of 1 late-stage trial awaiting results $768M market value “fund our operating expenses and capital expenditure requirements into mid-2028” · 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$ALKS — Alkermes plc. — ALKS 2680 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia	Trial results Phase 2	primary completion 2026-11-01 registry estimate NCT06843590	1 of 1 late-stage trial awaiting results $6.8B market value	registry date only — waiting for the company to guide one
$VIR — Vir Biotechnology, Inc. — Tobevibart+Elebsiran A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection	Trial results Phase 2	primary completion 2026-11-01 registry estimate NCT07142811	1 of 4 late-stage trials awaiting results $1.8B market value	registry date only — waiting for the company to guide one
$EIKN — Eikon Therapeutics, Inc. — EIK1001 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC	Trial results Phase 2	primary completion 2026-12-01 registry estimate NCT06246110	1 of 1 late-stage trial awaiting results $428M market value no approved products, says its 10-Q, 2026-08-13 “fund our operating expenses and capital expenditures into the second half of 2027” · 10-Q, 2026-08-13	registry date only — waiting for the company to guide one
$RNAC — Cartesian Therapeutics, Inc. — Descartes-08 Descartes-08 for Patients With Systemic Lupus Erythematosus	Trial results Phase 2	primary completion 2026-12-01 registry estimate NCT06038474	1 of 2 late-stage trials awaiting results $219M market value no approved products, says its 10-Q, 2026-08-06	this drug is on the slate
$RNAC — Cartesian Therapeutics, Inc. — Descartes-08 Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis	Trial results Phase 3	primary completion 2026-12-30 registry estimate NCT06799247	1 of 2 late-stage trials awaiting results $219M market value no approved products, says its 10-Q, 2026-08-06	this drug is on the slate
$LXEO — Lexeo Therapeutics, Inc. Gene Therapy for ACM Due to a PKP2 Pathogenic Variant	Trial results Phase 1/2	primary completion 2026-12-01 registry estimate NCT06109181	1 of 2 late-stage trials awaiting results $281M market value no approved products, says its 10-Q, 2026-08-12	registry date only — waiting for the company to guide one
$AVIR — Atea Pharmaceuticals, Inc. — BEM/RZR C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV	Trial results Phase 3	primary completion 2026-12-01 registry estimate NCT07037277	1 of 2 late-stage trials awaiting results $415M market value no approved products, says its 10-Q, 2026-08-12 “fund our planned operations through 2027” · 10-Q, 2026-08-12	registry date only — waiting for the company to guide one
$BEAM — Beam Therapeutics Inc. — BEAM-201 A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)	Trial results Phase 1/2	primary completion 2026-12-01 registry estimate NCT05885464	1 of 2 late-stage trials awaiting results $2.5B market value no approved products, says its 10-K, 2026-02-24	registry date only — waiting for the company to guide one
$PRAX — Praxis Precision Medicines, Inc. — Relutrigine A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine	Trial results Phase 3	primary completion 2026-12-01 registry estimate NCT07010471	1 of 2 late-stage trials awaiting results $7.8B market value no approved products, says its 10-K, 2026-02-19 “fund our operating expenditures and capital expenditure requirements necessary to advance our operating activities into 2028” · 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$MANE — Veradermics, Inc — VDPHL01 Safety and Efficacy of VDPHL01 in Males With AGA	Trial results Phase 3	primary completion 2026-12-01 registry estimate NCT06972264	1 of 3 late-stage trials awaiting results $4.9B market value no approved products, says its 10-Q, 2026-08-11 “fund our operating expenses and capital expenditure requirements into 2030” · 10-Q, 2026-08-11	this drug is on the slate
$OMER — Omeros Corporation — OMS906 Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria	Trial results Phase 2	primary completion 2026-12-01 registry estimate NCT06298955	1 of 1 late-stage trial awaiting results $1.4B market value	registry date only — waiting for the company to guide one
$SUPN — Supernus Pharmaceuticals, Inc. — BIS-001-ER BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures	Trial results Phase 1/2	primary completion 2026-12-30 registry estimate NCT03474770	1 of 2 late-stage trials awaiting results $2.6B market value generating cash from operations · XBRL, to 2026-06-30	registry date only — waiting for the company to guide one
$VNDA — Vanda Pharmaceuticals Inc. — VQW-765 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder	Trial results Phase 3	primary completion 2026-12-01 registry estimate NCT07221578	1 of 4 late-stage trials awaiting results $304M market value	registry date only — waiting for the company to guide one
$VIR — Vir Biotechnology, Inc. — Tobevibart+Elebsiran A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide	Trial results Phase 3	primary completion 2026-12-01 registry estimate NCT07128550	1 of 4 late-stage trials awaiting results $1.8B market value	registry date only — waiting for the company to guide one
$VIR — Vir Biotechnology, Inc. — Tobevibart + Elebsiran A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection	Trial results Phase 3	primary completion 2026-12-31 registry estimate NCT06903338	1 of 4 late-stage trials awaiting results $1.8B market value	registry date only — waiting for the company to guide one
$DNLI — Denali Therapeutics Inc. — DNL593 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)	Trial results Phase 1/2	primary completion 2026-12-01 registry estimate NCT05262023	1 of 5 late-stage trials awaiting results $3.3B market value	registry date only — waiting for the company to guide one
$IONS — Ionis Pharmaceuticals, Inc. — Donidalorsen A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)	Trial results Phase 3	primary completion 2026-12-01 registry estimate NCT05392114	1 of 8 late-stage trials awaiting results $7.6B market value	registry date only — waiting for the company to guide one
$MLTX — MoonLake Immunotherapeutics — Sonelokimab Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response	Trial results Phase 3	primary completion 2027-01-04 registry estimate NCT06641089	1 of 2 late-stage trials awaiting results $974M market value no approved products, says its 10-Q, 2026-08-10	registry date only — waiting for the company to guide one
$IDYA — IDEAYA Biosciences, Inc. — IDE196 (Darovasertib) IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Trial results Phase 2/3	primary completion 2027-01-15 registry estimate NCT05987332	1 of 2 late-stage trials awaiting results $3.7B market value no approved products, says its 10-Q, 2026-08-04	registry date only — waiting for the company to guide one
$PRAX — Praxis Precision Medicines, Inc. — Vormatrigine Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures	Trial results Phase 3	primary completion 2027-01-01 registry estimate NCT07505004	1 of 2 late-stage trials awaiting results $7.8B market value no approved products, says its 10-K, 2026-02-19 “fund our operating expenditures and capital expenditure requirements necessary to advance our operating activities into 2028” · 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$RCUS — Arcus Biosciences, Inc. A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies	Trial results Phase 2	primary completion 2027-01-01 registry estimate NCT05329766	1 of 3 late-stage trials awaiting results $3.3B market value no approved products, says its 10-Q, 2026-08-05 “fund our planned level of operations until at least the second half of 2028” · 10-Q, 2026-08-05	registry date only — waiting for the company to guide one
$EWTX — Edgewise Therapeutics, Inc. — EDG-5506 A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)	Trial results Phase 2	primary completion 2027-01-01 registry estimate NCT05540860	1 of 3 late-stage trials awaiting results $4.3B market value no approved products, says its 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$PCVX — Vaxcyte, Inc. — VAX-31 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49	Trial results Phase 3	primary completion 2027-01-01 registry estimate NCT07284654	3 late-stage trials awaiting results at this company $8.4B market value no approved products, says its 10-Q, 2026-08-05	this drug is on the slate
$XENE — Xenon Pharmaceuticals Inc. — Azetukalner An Open-Label Study of Azetukalner in Major Depressive Disorder	Trial results Phase 3	primary completion 2027-01-01 registry estimate NCT06922110	1 of 5 late-stage trials awaiting results $3.6B market value no approved products, says its 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$SIGA — SIGA Technologies — TPOXX Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS	Trial results Phase 2	primary completion 2027-01-01 registry estimate NCT04957485	1 of 1 late-stage trial awaiting results $247M market value generating cash from operations · XBRL, to 2026-06-30	registry date only — waiting for the company to guide one
$LXRX — Lexicon Pharmaceuticals — sotagliflozin A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy	Trial results Phase 3	primary completion 2027-01-01 registry estimate NCT06481891	1 of 1 late-stage trial awaiting results $837M market value	registry date only — waiting for the company to guide one
$OCUL — Ocular Therapeutix, Inc. — OTX-TKI (Axitinib Implant) Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration	Trial results Phase 3	primary completion 2027-01-08 registry estimate NCT06495918	1 of 1 late-stage trial awaiting results $1.7B market value “Based on our current operating plan, which includes estimates of anticipated cash inflows from DEXTENZA product sales and cash outflows from …” · 10-Q, 2026-08-03	registry date only — waiting for the company to guide one
$MIRM — Mirum Pharmaceuticals, Inc. — volixibat A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis	Trial results Phase 2	primary completion 2027-01-01 registry estimate NCT05050136	1 of 4 late-stage trials awaiting results $5.7B market value	registry date only — waiting for the company to guide one
$RARE — Ultragenyx Pharmaceutical Inc. — Setrusumab Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta	Trial results Phase 3	primary completion 2027-01-01 registry estimate NCT06636071	1 of 7 late-stage trials awaiting results $1.5B market value	registry date only — waiting for the company to guide one
$IRON — Disc Medicine, Inc. — DISC-3405 A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)	Trial results Phase 2	primary completion 2027-02-01 registry estimate NCT06985147	1 of 1 late-stage trial awaiting results $2.5B market value no approved products, says its 10-Q, 2026-07-30 “fund our current operating and capital expenditure plans and our debt service obligations into 2029” · 10-Q, 2026-07-30	registry date only — waiting for the company to guide one
$ABCL — AbCellera Biologics Inc. — ABCL635 Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause	Trial results Phase 1/2	primary completion 2027-02-01 registry estimate NCT07118891	1 of 1 late-stage trial awaiting results $4.8B market value no approved products, says its 10-Q, 2026-08-05	registry date only — waiting for the company to guide one
$MLTX — MoonLake Immunotherapeutics — Sonelokimab Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug	Trial results Phase 3	primary completion 2027-02-04 registry estimate NCT06641076	2 late-stage trials awaiting results at this company $974M market value no approved products, says its 10-Q, 2026-08-10	registry date only — waiting for the company to guide one
$OCGN — Ocugen, Inc. — OCU400 A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa	Trial results Phase 3	primary completion 2027-02-12 registry estimate NCT06388200	1 of 3 late-stage trials awaiting results $370M market value no approved products, says its 10-K, 2026-03-04	this drug is on the slate
$CGEM — Cullinan Therapeutics, Inc. — zipalertinib locally advanced or metastatic EGFR exon 20 insertion mutation NSCLC previously treated with platinum-based chemotherapy	FDA decision	2027-02-27 company-guided 8-K filed 2026-10-02 “An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.”	— $980M market value no approved products, says its 10-Q, 2026-08-06	more than 120 days out — back in review from 2026-10-30
$APMD — Apnimed, Inc. — Oxnimbi (AD109) Obstructive sleep apnea (OSA)	FDA decision	2027-02-28 company-guided 10-Q filed 2026-09-08 “The FDA review cycle is targeted to be 10-months from our NDA submission in April 2026, and the FDA has issued a Prescription Drug User Fee Act ("PDUFA") goal date of February 28, 2027, although the duration of the review may vary based on …”	— $995M market value no approved products, says its 10-Q, 2026-09-08	more than 120 days out — back in review from 2026-10-31
$VOR — Vor Biopharma Inc. — Telitacicept A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)	Trial results Phase 3	primary completion 2027-03-01 registry estimate NCT06456580	1 of 1 late-stage trial awaiting results $1.1B market value no approved products, says its 10-Q, 2026-08-11 “fund our operating expenses and capital expenditure requirements into early 2029” · 10-Q, 2026-08-11	registry date only — waiting for the company to guide one
$COGT — Cogent Biosciences, Inc. — CGT4859 A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors	Trial results Phase 1/2	primary completion 2027-03-01 registry estimate NCT06777316	1 of 1 late-stage trial awaiting results $5.5B market value no approved products, says its 10-Q, 2026-08-10 “fund our operating expenses and capital expenditure requirements into late 2028” · 10-Q, 2026-08-10	registry date only — waiting for the company to guide one
$OCGN — Ocugen, Inc. — OCU400 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis	Trial results Phase 1/2	primary completion 2027-03-01 registry estimate NCT05203939	1 of 3 late-stage trials awaiting results $370M market value no approved products, says its 10-K, 2026-03-04	this drug is on the slate
$EWTX — Edgewise Therapeutics, Inc. — EDG-5506 Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy	Trial results Phase 2	primary completion 2027-03-01 registry estimate NCT06100887	1 of 3 late-stage trials awaiting results $4.3B market value no approved products, says its 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$PCVX — Vaxcyte, Inc. — VAX-31 A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age	Trial results Phase 3	primary completion 2027-03-01 registry estimate NCT07365826	1 of 3 late-stage trials awaiting results $8.4B market value no approved products, says its 10-Q, 2026-08-05	this drug is on the slate
$PCVX — Vaxcyte, Inc. — VAX-31 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination	Trial results Phase 3	primary completion 2027-03-01 registry estimate NCT07425392	1 of 3 late-stage trials awaiting results $8.4B market value no approved products, says its 10-Q, 2026-08-05	this drug is on the slate
$CGEN — Compugen Ltd — COM701 A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer	Trial results Phase 1/2	primary completion 2027-03-01 registry estimate NCT06888921	1 of 1 late-stage trial awaiting results $222M market value “fund operations into 2029” · 20-F, 2026-03-02	registry date only — waiting for the company to guide one
$NUVB — Nuvation Bio Inc. — NUV-1511 Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors	Trial results Phase 1/2	primary completion 2027-03-01 registry estimate NCT06334432	1 of 1 late-stage trial awaiting results $2.0B market value	registry date only — waiting for the company to guide one
$VNDA — Vanda Pharmaceuticals Inc. Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient	Trial results Phase 1/2	primary completion 2027-03-01 registry estimate NCT07223632	1 of 4 late-stage trials awaiting results $304M market value	registry date only — waiting for the company to guide one
$DNLI — Denali Therapeutics Inc. — BIIB122 Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)	Trial results Phase 2	primary completion 2027-03-01 registry estimate NCT06602193	1 of 5 late-stage trials awaiting results $3.3B market value	registry date only — waiting for the company to guide one
$IONS — Ionis Pharmaceuticals, Inc. — Olezarsen (ISIS 678354) CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)	Trial results Phase 3	primary completion 2027-03-01 registry estimate NCT05681351	1 of 8 late-stage trials awaiting results $7.6B market value	registry date only — waiting for the company to guide one
$AQST — Aquestive Therapeutics, Inc. — Anaphylm (dibutepinephrine) Treatment of Type I allergic reactions, including anaphylaxis	FDA decision	2027-03-16 company-guided 8-K filed 2026-10-15 “On October 15, 2026, Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for …”	— $586M market value	more than 120 days out — back in review from 2026-11-16
$AQST — Aquestive Therapeutics, Inc. — LIBERVANT (diazepam) buccal film Acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients with epilepsy ages 6 to 11	FDA decision	2027-03-29 company-guided 8-K filed 2026-10-14 “The NDA has a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2027.”	— $586M market value	more than 120 days out — back in review from 2026-11-29
$ETON — Eton Pharmaceuticals, Inc. — LIBERVANT (diazepam) Buccal Film Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters or acute repetitive seizures) in patients with epilepsy ages 6 to 11	FDA decision	2027-03-29 company-guided 8-K filed 2026-10-14 “The NDA has a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2027.”	— $1.7B market value generating cash from operations · XBRL, to 2026-06-30	more than 120 days out — back in review from 2026-11-29
$KYTX — Kyverna Therapeutics, Inc. — Anti-CD19 CAR T-Cell Therapy (KYSA-7) KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis	Trial results Phase 2	primary completion 2027-04-01 registry estimate NCT06384976	1 of 1 late-stage trial awaiting results $423M market value no approved products, says its 10-Q, 2026-08-11	registry date only — waiting for the company to guide one
$IDYA — IDEAYA Biosciences, Inc. — IDE196 (Darovasertib) (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma	Trial results Phase 2	primary completion 2027-04-30 registry estimate NCT05907954	1 of 2 late-stage trials awaiting results $3.7B market value no approved products, says its 10-Q, 2026-08-04	registry date only — waiting for the company to guide one
$VSTM — Verastem, Inc. — VS-7375 Second-line metastatic pancreatic ductal adenocarcinoma (2L mPDAC)	Trial results	2027-04-01 – 2027-06-30 company-guided 8-K filed 2026-10-14	1 late-stage trial awaiting results at this company $717M market value	this drug is on the slate
$IONS — Ionis Pharmaceuticals, Inc. — ION717 PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717	Trial results Phase 1/2	primary completion 2027-04-01 registry estimate NCT06153966	1 of 8 late-stage trials awaiting results $7.6B market value	registry date only — waiting for the company to guide one
$IRD — Opus Genetics, Inc. — OPGx-BEST1 BEST1-related retinal disease	Trial results	2027-04-01 – 2027-06-30 company-guided 8-K filed 2026-09-09 “Q2 2027 BEST1 Cohort 2 results”	— $412M market value	more than 120 days out — back in review from 2026-12-02
$IRON — Disc Medicine, Inc. — bitopertin erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP)	FDA decision	2027-05-01 – 2027-08-31 company-guided 8-K filed 2026-10-19 “Based on these results, Disc plans to resubmit a New Drug Application (NDA) to the U.S. FDA by the end of 2026, with an FDA decision anticipated by mid-2027.”	1 late-stage trial awaiting results at this company $2.5B market value no approved products, says its 10-Q, 2026-07-30 “fund our current operating and capital expenditure plans and our debt service obligations into 2029” · 10-Q, 2026-07-30	more than 120 days out — back in review from 2027-01-01
$MBX — MBX Biosciences, Inc. — MBX 2109 Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism	Trial results Phase 2	primary completion 2027-05-27 registry estimate NCT06531941	1 of 1 late-stage trial awaiting results $2.8B market value no approved products, says its 10-Q, 2026-08-06 “fund our operating expenses and capital expenditure requirements into 2029” · 10-Q, 2026-08-06	registry date only — waiting for the company to guide one
$ZURA — Zura Bio Ltd — Tibulizumab Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)	Trial results Phase 2	primary completion 2027-05-01 registry estimate NCT06843239	1 of 2 late-stage trials awaiting results $383M market value no approved products, says its 10-Q, 2026-08-11 “fund our operating expenses and capital requirements through at least the end of 2028” · 10-Q, 2026-08-11	registry date only — waiting for the company to guide one
$RCUS — Arcus Biosciences, Inc. — Zimberelimab and Domvanalimab Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer	Trial results Phase 2	primary completion 2027-05-01 registry estimate NCT04736173	1 of 3 late-stage trials awaiting results $3.3B market value no approved products, says its 10-Q, 2026-08-05 “fund our planned level of operations until at least the second half of 2028” · 10-Q, 2026-08-05	registry date only — waiting for the company to guide one
$CBIO — Crescent Biopharma, Inc. — CR-001 (SKB118) Locally advanced or metastatic NSCLC	Trial results	2027-05-01 – 2027-08-31 company-guided 8-K filed 2026-10-15 “A Phase 2 trial of CR-001 (SKB118) and sac-TMT in participants with locally advanced or metastatic NSCLC is ongoing with initial data expected in mid-2027;”	— $548M market value no approved products, says its 10-Q, 2026-07-30	more than 120 days out — back in review from 2027-01-01
$SRPT — Sarepta Therapeutics, Inc. — Delandistrogene moxeparvovec (SRP-9001) A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)	Trial results Phase 3	primary completion 2027-05-31 registry estimate NCT05881408	1 of 2 late-stage trials awaiting results $2.0B market value	registry date only — waiting for the company to guide one
$RYTM — Rhythm Pharmaceuticals, Inc. — RM-718 A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment	Trial results Phase 1/2	primary completion 2027-05-07 registry estimate NCT06239116	1 of 2 late-stage trials awaiting results $6.6B market value	registry date only — waiting for the company to guide one
$INDP — Indaptus Therapeutics, Inc. — DECOY20 with or without tislelizumab Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors	Trial results Phase 1/2	primary completion 2027-06-30 registry estimate NCT05651022	1 of 1 late-stage trial awaiting results $380M market value no approved products, says its 10-K, 2026-03-17	registry date only — waiting for the company to guide one
$AVLN — Avalyn Pharma Inc. — AP01 A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis	Trial results Phase 2	primary completion 2027-06-01 registry estimate NCT06329401	1 of 1 late-stage trial awaiting results $1.2B market value no approved products, says its 10-Q, 2026-08-12 “fund our operating expenses and capital expenditures into 2029” · 10-Q, 2026-08-12	registry date only — waiting for the company to guide one
$KYMR — Kymera Therapeutics, Inc. — KT-621 A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis	Trial results Phase 2	primary completion 2027-06-01 registry estimate NCT07217015	1 of 1 late-stage trial awaiting results $9.2B market value no approved products, says its 10-Q, 2026-08-05 “fund our operations into 2029” · 10-Q, 2026-08-05	registry date only — waiting for the company to guide one
$FDMT — 4D Molecular Therapeutics, Inc. — 4D-150 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration	Trial results Phase 3	primary completion 2027-06-01 registry estimate NCT06864988	1 of 2 late-stage trials awaiting results $800M market value no approved products, says its 10-Q, 2026-08-13	registry date only — waiting for the company to guide one
$MGTX — MeiraGTx Holdings plc — AAV2-hAQP1 gene therapy A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia	Trial results Phase 2	primary completion 2027-06-01 registry estimate NCT05926765	1 of 2 late-stage trials awaiting results $1.1B market value no approved products, says its 10-Q, 2026-08-13 “Based on our cash, cash equivalents, accounts receivable, accounts receivable - related party, unbilled receivables - related party and tax incentive …” · 10-Q, 2026-08-13	registry date only — waiting for the company to guide one
$ORKA — Oruka Therapeutics, Inc. — ORKA-001 Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis	Trial results Phase 2	primary completion 2027-06-01 registry estimate NCT07290569	1 of 2 late-stage trials awaiting results $5.4B market value no approved products, says its 10-Q, 2026-08-10	registry date only — waiting for the company to guide one
$BLTE — Belite Bio, Inc. — Tinlarebant Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy	Trial results Phase 3	primary completion 2027-06-30 registry estimate NCT05949593	1 of 2 late-stage trials awaiting results $6.7B market value no approved products, says its 20-F, 2026-03-31	registry date only — waiting for the company to guide one
$MANE — Veradermics, Inc — VDPHL01 Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)	Trial results Phase 3	primary completion 2027-06-01 registry estimate NCT07146022	1 of 3 late-stage trials awaiting results $4.9B market value no approved products, says its 10-Q, 2026-08-11 “fund our operating expenses and capital expenditure requirements into 2030” · 10-Q, 2026-08-11	this drug is on the slate
$IONS — Ionis Pharmaceuticals, Inc. — Olezarsen (formerly AKCEA-APOCIII-LRX) A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen	Trial results Phase 3	primary completion 2027-06-01 registry estimate NCT05185843	1 of 8 late-stage trials awaiting results $7.6B market value	registry date only — waiting for the company to guide one
$BIOA — BioAge Labs, Inc. — BGE-102 diabetic macular edema (DME)	Trial results	2027-07-01 – 2027-12-31 company-guided 8-K filed 2026-10-02 “Topline results expected in the second half of 2027; the results are expected to inform the development strategy in other NLRP3-driven retinal diseases, including geographic atrophy.”	1 late-stage trial awaiting results at this company $328M market value no approved products, says its 10-Q, 2026-08-05 “fund our operations and capital expenses through 2029” · 10-Q, 2026-08-05	more than 120 days out — back in review from 2027-03-03
$LXEO — Lexeo Therapeutics, Inc. — LX2006 Friedreich ataxia	Trial results	2027-07-01 – 2027-12-31 company-guided 8-K filed 2026-09-22 “The program remains on track to provide a topline data readout in the second half of 2027.”	2 late-stage trials awaiting results at this company $281M market value no approved products, says its 10-Q, 2026-08-12	more than 120 days out — back in review from 2027-03-03
$ODTX — Odyssey Therapeutics, Inc. — OD-001 Inflammatory bowel disease (IBD)	Trial results	2027-07-01 – 2027-12-31 company-guided 8-K filed 2026-10-20 “OD-001 is being advanced toward late-stage monotherapy and combination trials concurrently, with topline results expected H2 2027”	— $1.1B market value no approved products, says its 10-Q, 2026-08-06 “fund our operating expenses and capital expenditures into the second half of 2028” · 10-Q, 2026-08-06	more than 120 days out — back in review from 2027-03-03
$LTGO — Latigo Biotherapeutics, Inc. — onzotrigine Moderate-to-severe acute pain after bunionectomy surgery	Trial results	2027-07-01 – 2027-12-31 company-guided 8-K filed 2026-09-03 “Expect to report topline results from the Phase 3 bunionectomy and open-label safety clinical trials in the second half of 2027.”	— $1.2B market value no approved products, says its 10-Q, 2026-09-03 “fund our projected operating expenses and capital expenditure requirements into 2029” · 10-Q, 2026-09-03	more than 120 days out — back in review from 2027-03-03
$MEOBF — Mesoblast, Ltd. — Rexlemestrocel-L combined with HA Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain	Trial results Phase 3	primary completion 2027-07-01 registry estimate NCT06325566	1 of 1 late-stage trial awaiting results $1.9B market value	registry date only — waiting for the company to guide one
$VKTX — Viking Therapeutics, Inc. — VK2735 VK2735 for Weight Management Phase 3	Trial results Phase 3	primary completion 2027-07-01 registry estimate NCT07104500	1 of 2 late-stage trials awaiting results $4.0B market value	registry date only — waiting for the company to guide one
$VKTX — Viking Therapeutics, Inc. — VK2735 VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)	Trial results Phase 3	primary completion 2027-07-01 registry estimate NCT07104383	1 of 2 late-stage trials awaiting results $4.0B market value	registry date only — waiting for the company to guide one
$GLUE — Monte Rosa Therapeutics, Inc. — MRT-8102 gout	Trial results	2027-07-01 – 2027-12-31 company-guided 8-K filed 2026-10-01 “Initial data are expected in H2 2027.”	— $1.0B market value “support our cash runway into 2029” · 10-Q, 2026-08-06	more than 120 days out — back in review from 2027-03-03
$CAMP — Camp4 Therapeutics Corp —	Trial results	2028-01-01 – 2028-06-30 company-guided 8-K filed 2026-09-28 “The Company is targeting a topline data readout from the ASCEND clinical trial in the first half of 2028.”	— $245M market value no approved products, says its 10-Q, 2026-08-13 “Based on our current operating plan, we estimate that our cash and cash equivalents as of June 30, 2026, together with the net proceeds of $46.9 …” · 10-Q, 2026-08-13	more than 120 days out — back in review from 2027-09-03
$PHAT — Phathom Pharmaceuticals, Inc. — VOQUEZNA (vonoprazan) Non-Erosive Gastroesophageal Reflux Disease (NERD)	Trial results	2028-01-01 – 2028-12-31 company-guided 8-K filed 2026-09-29 “Topline results are expected in the first quarter of 2028.”	1 late-stage trial awaiting results at this company $595M market value	more than 120 days out — back in review from 2027-09-03
$XFOR — X4 Pharmaceuticals, Inc — mavorixafor chronic neutropenia	Trial results	2028-01-01 – 2028-06-30 company-guided 8-K filed 2026-10-08 “We expect to reach several key milestones in the near term, including completing enrollment in our Phase 3 4WARD trial this year and reporting topline results in the first half of 2028.”	— $288M market value	more than 120 days out — back in review from 2027-09-03
$GPCR — Structure Therapeutics Inc. — aleniglipron Chronic weight management in adults with obesity or overweight, including those with type 2 diabetes mellitus	Trial results	2028-07-01 – 2028-12-31 company-guided 8-K filed 2026-09-08 “ALENIGLIPRON On track to complete enrollment by 1H 2027 and topline data in 2H 2028”	— $2.3B market value no approved products, says its 10-Q, 2026-08-06 “fund our projected operations and key clinical milestones through the end of 2028” · 10-Q, 2026-08-06	more than 120 days out — back in review from 2028-03-03
$XERS — Xeris Biopharma Holdings, Inc. — XP-8121 Hypothyroidism	Trial results	2028-09-01 – 2028-12-31 company-guided 8-K filed 2026-09-09 “the expected initiation of Cornerstone by year-end 2026, the expected initiation of Touchstone in 2027 and completion of Touchstone in time for inclusion in the Company's NDA submission, and the expected timing of topline results in late …”	— $1.8B market value generating cash from operations · XBRL, to 2026-06-30	more than 120 days out — back in review from 2028-05-04
$TARS — Tarsus Pharmaceuticals, Inc. — gildeuretinol (ALK-001) Stargardt disease	Trial results	2029-01-01 – 2029-12-31 company-guided 8-K filed 2026-09-10 “ALK-001 has received Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for Stargardt disease and is currently being evaluated in the global NORTHSTAR …”	1 late-stage trial awaiting results at this company $3.6B market value no approved products, says its 10-Q, 2026-08-06 generating cash from operations · XBRL, to 2026-06-30	more than 120 days out — back in review from 2028-09-03

Exclusions

Candidates the scan surfaced and we decided not to cover, with the reason. Publishing the misses is the point: a slate you can pick after the fact is not a slate. A catalyst that is only waiting for a date is on the radar above, not here.

Candidate	Found	Source	Reason not covered
$ATTO — Attovia Therapeutics, Inc. — ATTO-1310	2026-09-12 13:20 ET	edgar_fts	duplicate
$BHVN — Biohaven Ltd. — BHV-7000	2026-09-12 13:20 ET	edgar_fts	The filing does not establish a concentrated company or the dominant driver.